Wells Fargo’s Caris Life Sciences CAI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$422K Buy
23,689
+6,439
+37% +$115K ﹤0.01% 4745
2026
Q1
$308K Buy
17,250
+8,255
+92% +$180K ﹤0.01% 4431
2025
Q4
$243K Buy
8,995
+7,225
+408% +$203K ﹤0.01% 4957
2025
Q3
$53.5K Buy
1,770
+470
+36% +$15K ﹤0.01% 5533
2025
Q2
$34.7K Buy
+1,300
New +$35K ﹤0.01% 5631

Other funds holding CAI

Wells Fargo's CAI Position: Q2 2026 in Review

Wells Fargo increased its Caris Life Sciences (CAI) stake by 37% in Q2 2026, buying an estimated $115K and bringing the position to 23,689 shares worth $422K. The position accounts for ﹤0.01% of the portfolio, ranked #4745.

Wells Fargo first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Wells Fargo held 23,689 shares of Caris Life Sciences worth $422K as of Q2 2026.
  • Wells Fargo bought 6,439 Caris Life Sciences shares in Q2 2026, an estimated $115K.
  • Caris Life Sciences made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4745 holding.
  • Wells Fargo first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.